Romosozumab Completed Phase 1 Trials for Osteoporosis / Postmenopausal Osteoporosis (PMO) Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01588509Transition From Alendronate to Romosozumab (AMG 785)